middle.news
Telix Reports 11% Q1 Revenue Growth and Advances Prostate Cancer Therapy Trials
8:40am on Tuesday 7th of April, 2026 AEST
•
Healthcare
Read Story
Telix Reports 11% Q1 Revenue Growth and Advances Prostate Cancer Therapy Trials
8:40am on Tuesday 7th of April, 2026 AEST
Key Points
Q1 2026 revenue up 11% quarter-over-quarter to US$230 million
FY 2026 revenue guidance reaffirmed at US$950–970 million
Positive Phase 3 ProstACT trial results for prostate cancer therapy TLX591-Tx
Regulatory submissions advanced for imaging agents TLX101-Px and TLX591-Px
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TELIX PHARMACEUTICALS (ASX:TLX)
OPEN ARTICLE